

































































Virtual Reality–Based and Conventional Visual Field
Examination Comparison in Healthy and Glaucoma Patients
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Purpose: Clinically evaluate the noninferiority of a custom virtual reality (VR) perime-
try system when compared to a clinically and routinely used perimeter on both healthy
subjects and glaucoma patients.
Methods: We use a custom-designed VR perimetry system tailored for visual field
testing. The system uses Oculus Quest VR headset (Facebook Technologies, LLC, Bern,
Switzerland), that includes a clicker for participant response feedback. A prospective,
single center, study was conducted at the Department of Ophthalmology of the Bern
University Hospital (Bern, Switzerland) for 12 months. Of the 114 participants recruited
70 subjects (36healthy and34glaucomapatientswith early tomoderate visual field loss)
were included in the study. Participants underwent perimetry tests on an Octopus 900
(Haag-Streit, Köniz, Switzerland) as well as on the custom VR perimeter. In both cases,
standard dynamic strategy (DS) was used in conjunction with the G testing pattern.
Collected visual fields (VFs) from both devices were then analyzed and compared.
Results: Highmean defect (MD) correlations between the two systems (Spearman, ρ ≥
0.75) were obtained. The VR system was found to slightly underestimate VF defects in
glaucoma subjects (1.4 dB). No significant bias was foundwith respect to eccentricity or
subject age. On average, a similar number of stimuli presentations per VFwas necessary
when measuring glaucoma patients and healthy subjects.
Conclusions: This study demonstrates that a clinically usedperimeter and theproposed
VR perimetry system have comparable performances with respect to a number of
perimetry parameters in healthy and glaucoma patients with early to moderate visual
field loss.
Translational Relevance: This suggests that VR perimeters have the potential to assess
VFs with high enough confidence, whereby alleviating challenges in current perimetry
practices by providing a portable and more accessible visual field test.
Introduction
Glaucoma is one of the leading causes of blind-
ness1,2 and currently affects about 80 million people
worldwide. Concurrently, the number of glaucoma
patients is expected to rise toward 112 million by
2040.3 Visual field (VF) testing is an integral part of
glaucoma diagnosis and its follow-up monitoring4 and
standard automated perimetry (SAP) is the current
gold standard VF testing approach.5 Using perime-
ters, SAP quantitatively assesses an individual’s visual
function across the field of vision. More precisely,
based on an interactive procedure involving participant
responses to a sequence of light stimuli, SAP deter-
mines sensitivity thresholds (ST) at specific retinotopic
locations, resulting in a measured VF.6 Collected VFs
can then be evaluated by comparing corresponding
STs to an age-matched normative database to identify
perceptual defects typical in glaucoma patients and
other neuro-ophthalmic conditions.
While SAP is an essential tool in glaucoma diagno-
sis andmonitoring, SAP has important limitations and
weaknesses. Critically, SAP acquisitions, although fast
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alternatives exist (e.g., 2–5 minutes),7–10 are generally
long-lasting with typical testing times around 6 to 8
minutes per eye,6 during which the patient is required
to maintain high levels of concentration.11 Such long
acquisition times, combined with the slightly forward
leaning position of the participant has been reported
to be uncomfortable and highly taxing for participants,
leading to low-quality measurements,11–14 as well as
unwillingness in patients to participate in the follow-
up examinations.15,16 Furthermore, the management
capacity in clinics is limited by the high-cost and
large space requirements of standard perimeters and
have already become overloaded with the increasing
number of glaucoma patients.17 As reported by Foot
and MacEwen,18 patients suffer from preventable loss
due to the delays in the follow-up appointments, which
highlights the incapacity of current eye care services.16
To ease these limitations, the use of portable alter-
natives has drawn strong attention. These have broadly
been categorized in tablet or head-mounted device
(HMD) systems. Tablet perimeters such as the Visual-
Fields Easy,19,20 Melbourne Rapid Fields (MRF),21–27
or Eyecatcher28,29 offer different solutions that use
either gaze-based or touch-based feedback systems.
These have shown to have fairly comparable test-retest
variability with traditional perimeters under specific
conditions.
HMD that used wired or wireless connections to a
computer have also been used for standard VF testing.
An early example was the tethered system presented
by Chan et al.30 The device showed good agreement
withHumphrey Field Analyzer (HFA; Carl Zeiss, Jena,
Germany) on 13 normal subjects and nine subjects
with VF defects in terms of mean sensitivity (MS). A
follow-up study using a virtual reality perimeter, Kasha
Visual Field system, demonstrated that the system
could achieve an equal sensitivity with neurosurgery
patients.31 Wroblewski et al.32 introduced a HMD,
VirtualEye, with two feedback options, namely manual
(i.e., mouse click) and visual grasp (i.e., directing the
gaze to the target). This system had a systematic bias
of 4 to 6 dB and an average standard deviation of
5 dB compared to HFA while having fixation issues
with visual grasp mode. The imo system (CREWT
Medical Systems, Tokyo, Japan) implements monoc-
ular and binocular testing and showed high correla-
tion with HFA on 20 glaucoma patients.33 Due to the
HMD’s heaviness, the authors also propose a station-
ary stand to perform the test. Tsapakis et al.34 intro-
duced a VF testing system using virtual reality (VR)
glasses for a smartphone and showed high correlation
with HFA. Along this line, most recent HMD perime-
ters leverage the rapid advances in VR technology and
are starting to be introduced as medical devices for
clinical use. One such system is theVividVision Perime-
ter (VividVision, Inc., SanFrancisco, CA), with patient
feedback based on gaze direction and was shown SAP
consistent measurement variability.35 Alternatively, the
VisuALL (Olleyes Inc., Summit, NJ) VR perimeter
showed moderate correlation with HFA (correlation
coefficient r = 0.5 for normal, r = 0.8 for glaucoma
subjects) while having longer examination times.36
In general, the aforementioned solutions could
deliver portability in perimetry systems up to a limited
extent. While some devices are not completely portable
due to the device weight or cable requirement to
connect to the computer, others either suffer from poor
correlation with standard perimeters or induce longer
examinations times. Furthermore, the comparisonwith
the existing perimeters has usually been limited to
individual STs or mean sensitivity values, which are
device-dependent thus potentially misleading. In this
paper, we introduce a novel VR perimeter and demon-
strate its performance on a clinical population of both
normal healthy subjects and glaucoma patients. We
compare the system directly with a standard clinical
perimeter, Octopus 900 (Haag-Streit). To perform a
direct comparison between the two devices, we created
a normative database for the proposed VR perimetry
system. Mean defect (MD) values from both devices
were contrasted to assess the noninferiority of the
presented VR system.
Methods
We conducted a quantitative prospective random-
ized single-center study on 114 subjects with healthy
and glaucomatous eyes in the Department of Ophthal-
mology, BernUniversityHospital, fromAugust 2019 to
November 2020. The aim of the study was to evaluate
the performance of a proposed VR perimetry system
compared to a conventional perimeter.
All data captured throughout the study was stored
either locally or using a secure web-based electronic
data capturing tool. The data was anonymized for
the data analysis. The study protocol with the identi-
fier number 2018-01902 was approved by the Bernese
Ethics Committee, Switzerland, and adhered to the
tenets of the Declaration of Helsinki. Informed
consent was obtained from all subjects in advance to
the study procedure.
Subjects
Patients with healthy or glaucomatous eyes were
recruited from the glaucoma clinic at the Depart-
ment of Ophthalmology, Bern University Hospital.
The general inclusion criteria were an age between
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Table 1. Age,MD, and sLV Statistics of Subjects Included in the Study, AlongwithMean, StandardDeviations (SD),
and Max/Min Values
#Patients Age (Mean/SD [Min, Max]) MD (Mean/SD [Min, Max]) sLV (Mean/SD [Min, Max])
Healthy 36 60.67/10.64 [40.00, 77.00] 0.08/1.29 [–2.30, 4.00] 2.13/0.55 [1.10, 3.70]
Glaucoma 34 65.06/7.15 [53.00, 79.00] 5.69/2.53 [2.10, 10.30]] 6.26/2.63 [2.00, 11.80]
All 70 62.80/9.38 [40.00, 79.00] 2.80/3.44 [–2.30, 10.30] 4.14/2.79 [1.10, 11.80]
Figure 1. Oculus Quest VR headset with the Bluetooth connected
clicker.
40 and 80 years, refractive error within ±5 diopter
spherical equivalent, an astigmatism less than −3
diopter, a visual acuity of more than 0.3 logMar, a
history of at least one perimetry examination and
less than 25% false positive and negative errors for
both examinations (VR or traditional system). Healthy
subjects had mean defects (MD) of less than 2 dB;
glaucomatous subjects were diagnosed with either
primary open-angle, pseudoexfoliation, or primary
angle-closure glaucoma, with early to moderate visual
field loss (+2 dB < MD < +12 dB). Exclusion crite-
ria were the inability to follow the procedure, insuf-
ficient knowledge of the project language (German
or French), history of ocular diseases other than
glaucoma or cataract, or any other visual pathway
conditions that might affect visual field testing (e.g.,
pituitary lesions, demyelinating diseases). Patients
having an history of epilepsy were also excluded.
In this study, 70 out of 114 subjects qualified for the
study (36 healthy and 34 glaucomatous) meeting the
inclusion criteria (i.e., false positive and negative errors
less than 25% for each examination with the virtual
reality system and the Octopus 900 perimeter).
Table 1 summarizes the statistics of the subjects
included in the study.
Virtual Reality System
Our VR system uses the commercially available
Oculus Quest VR headset (see Fig. 1) to simulate a
standard visual field test. We implemented the same
testing principles as in the Octopus 900 using Unity
2019.3.0 Alpha 5 (released on June 6, 2019). We used
light stimuli of Goldmann size III for presentation on
the VR screenwhich passes through the VR lens system
to then be projected onto the retina of the subject.
Subject feedback is provided with a remote clicker
connected via Bluetooth.
Figure 2 shows the measured nonlinear relation-
ship of the RGB inputs of the VR headset and the
output luminance of the VR display. The standard
background luminance level for perimetry of 10 cd/m2
is equivalent to an RGB level of 94, enabling a theoret-
ical dynamic range of 161 input levels, or 78 cd/m2
luminance output range. Thus, to establish clinically
relevant intensities for VF testing, the dB values are
chosen so that the resolution is larger for increased dB
values compared to lower dB values. Eq. 1 describes the
used relation of luminance and decibel scale:
dB = 10 ∗ log10
Lmax
Lcurrent − Lbackground (1)
where Lmax is the maximum luminance of the system
(i.e., 88 cd/m2), Lcurrent is the intensity of the displayed
stimulus, and Lbackground is 10 dB. To further correct
spherical and cylindrical aberrations, custom designed
lens holders were used to embed standard trial lenses in
the VR system. The correction values were recomputed
for the VR headset to establish the same lens correction
as in Octopus 900.
To allow our system to produce mean defect values,
we constructed a normative database using the data
acquired fromhealthy subjects that were included in the
study (See Table 1). Based on theOctopus 900’s conven-
tion, we define a defect or total deviation (TD) at test
location l, dl as:
dl = STnorml − STl , (2)
where STlnorm denotes the age-matched sensitivity
threshold for the test location l and STl is the measured
ST for the test location l. As an illustration, Figure 3
shows normative values with respect to the eccentricity
of the test locations for subjects aged 55.
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Figure 2. Screen calibration measurements of the VR headset shows relationship of RGB values to luminance and dB values, respectively.
The vertical lines indicate the values that are used for the dynamic units of the testing strategy.
Figure 3. Example of sensitivity threshold values for 55-year-old
subjects. Normative valuesdecrease towards theperiphery, showing
the “hill of vision,” as in other perimetry devices.6
Visual Field Acquisition
All subjects performed a visual field test using the
custom designed VR system in addition to a visual field
test using anOctopus900 (Haag-Streit). Both examina-
tions took place the same day during the same session.
VFs acquired with both devices used the dynamic strat-
egy (DS),37,38 which is routinely used for glaucoma
patients in the Bern University Hospital Eye Clinic.
The G program, that includes 59 test locations within
30°, was used for both systems as well.
For each subject, the order of two examinations was
randomized to avoid fatigue-based biases. A randomly
selected eye was chosen for the study in the case that
both eyes met the defined inclusion criteria. Eye track-
ing option was turned off in Octopus 900 when testing
the study eye, but the patient was monitored through-
out the examination to ensure gaze fixation at the
central target. As monitoring was not possible for
the VR perimetry, we implemented blind spot control
using the Heijl-Krakau method39,40 to check the gaze
fixation. A beeping sound was used for each test to
maintain the subject’s attention. There was (at least) a
5 minute break between Octopus 900 and VR device
examinations.
Data Analysis/Statistics
To provide a direct comparison in MD differences
between both systems, we will compute the correlations
of corresponding VF using a Spearman ranked corre-
lation coefficient (i.e., ρ, which takes values between –1
and 1, where 1/–1 indicates a strong relationship, while
values closer to 0 suggests weak or no relationship).
Distribution of differences in MDs is also provided
to show the existence of any estimation bias, whereby
a distribution with a mean closer to 0 indicates an
unbiased measurement. To investigate performance
dependency on the VF topography, we also provide
TD differences with respect to the eccentricity and
spatial location. Additionally, we compute Bland-
Altman plots41 to determine the agreement between two
measurement techniques. This allows for the identifica-
tion systematic of bias as well as the limits of agree-
ments that give the range of differences. In this case, it
is defined to include 95% of the sample differences. If
the range between the limits of agreement is clinically
acceptable, then both systems can be used interchange-
ably. In addition, we computed distributions of exami-
nation times for both devices across different subpop-
ulations. Similarly, to further analyze the differences
between both device performance in terms of time, the
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distributions of the number of presented stimuli are
also given.
Illustrative examples are additionally provided to
qualitatively assess VFs measured by the proposed VR
system compared to those acquired by the Octopus
900. The error performance at the isolated defects is
analyzed to further assess the acquisition ability of the
VR system.
Lastly, we provide comparison of reliability indices
(e.g., false positive/negative errors) of both devices.
Results
Figure 4 shows the correlations between the
measured MDs for the Octopus 900 and the VR
perimetry system. The Spearman’s ranked correlation
coefficients ρ is 0.77 (P value < 0.00001), 0.50 (P <
0.001), and 0.70 (P < 0.0001) for all, healthy, and
glaucoma patients, respectively.
Looking at the distribution of differences in MDs
yielded means and standard deviations (SD) of 0.6
(SD = 2.3), –0.1 (SD = 2.2), and 1.4 (SD = 2.1)
for all, healthy, and glaucoma subjects, respectively.
The distributions are also presented in Figure 5 where
no strong bias is apparent, but rather slight shifts
towards underestimating MDs (compared to Octopus
900) in glaucoma subjects and slight overestimates are
seen for healthy subjects. For all cases, however, the
mean difference is less than 1.5 dB in both directions
with a standard deviation of 2 dB. Figure 6 presents
the MD estimation bias with respect to patient age.
Accordingly, for healthy patients, VR perimetry shows
slight overestimation for subjects aged less than 60 and
underestimates subjects of age greater than 60. For
glaucoma patients, VR perimetry tended to slightly
underestimate across all age groups, while there is
no statistically significant difference in the estimation
bias with respect to the age (P > 0.1, Kruskal-Wallis
test).
Figure 7 depicts the difference between total devia-
tion measurements given by the two systems and distri-
butions with respect to the eccentricity of the corre-
sponding locations for both healthy and glaucoma-
tous subject groups. Accordingly, no significant depen-
dency is observed for either healthy or glaucomatous
subjects (Kruskal-Wallis test, P > 0.1). For glauco-
matous subjects, however, the standard deviation of
differences slightly increases with increasing eccen-
tricity. This can be further observed in Figure 8,
which show TD differences (mean and standard devia-
tion) with respect to the spatial location. For healthy
patients, we observed homogeneous distribution of TD
differences across the VF except a specific peripheral
location where relatively higher underestimation by the
VR system was observed. As for glaucoma cases, we
observed higher TD bias at peripheral locations with
no particular trend and relatively low variance in the
inferior temporal region.
The Bland-Altman difference plots for all, normal,
and glaucomatous subjects are given in Figure 9, with
the middle line corresponding to the mean difference
and the upper and lower lines corresponding to 95%
limits of agreements (LoA).
Figure 10 compares the examination duration for
Octopus 900 and VR perimetry for all, healthy, and
glaucomatous patients separately. The median exami-
nation duration for the VR system is 6.57 minutes (CI:
[6.41, 6.74]) while the median examination duration for
Octopus 900 was 5.75 minutes (CI: [5.67, 5.96]) with
P < 0.0001 (Kruskal-Wallis test). For healthy patients,
there is a significant difference between VR median
examination duration (6.70 minutes, CI: [6.50, 6.85])
and Octopus 900 examination duration (5.46 minutes,
CI: [5.40, 5.67], P < 0.0001 (Kruskal-Wallis test)).
In contrast, the difference is not statistically signifi-
cant in glaucoma patients (P > 0.1, Kruskal-Wallis
Figure 4. Mean defect correlations between all (left), healthy (middle), and glaucoma (right) subjects. Spearman’s rank correlation coeffi-
cient ρ values with the corresponding P values are given on each plot. Red dotted line corresponds to best fit line.
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Figure 5. Estimation bias of MDmeasurements for all (left), healthy (middle), and glaucoma (right) patients. Mean and standard deviations
(SD) are given in each plot.
Figure 6. Estimation bias on MD estimation with respect to the age of the patient for healthy (left) and glaucoma (right) patients. P values
are provided on each plot (Kruskal-Wallis test).
test) between VR (6.39 minutes, CI: [6.20, 6.73]) and
Octopus 900 (6.27 minutes, CI: [5.97–6.65]) devices.
Figure 11 shows the distribution of the number
of presented stimuli (excluding all the catch trials) by
Octopus 900 and by the VR perimetry for all, healthy,
and glaucoma subjects. The median number of stimuli
presented by the VR system is 136.50 (CI: [133.50,
139.50]) while the median number of stimuli presented
by Octopus 900 is 129.50 (CI: [126.00, 132.00]). For
healthy patients, the number of stimuli presented by the
VR system (139.00, CI: [134.00, 142.00]) is larger than
that of Octopus 900 (125.00, CI: [124.00–126.50]); P <
0.0.0001, Kruskal-Wallis test). For glaucoma patients,
VR system (135.00, CI: [129.00–139.00]) presented
slightly fewer stimuli than Octopus 900 (137.00, CI:
[132.00–150.00]; P > 0.1, Kruskal-Wallis test).
Qualitative examples for healthy (see Fig. 12)
and glaucomatous (see Fig. 13) VFs are given. The
total deviation values are scaled to allow comparison
between Octopus 900 and VR perimetry acquisitions.
In addition, we provide the performance of VRperime-
try when measuring isolated defects in Figure 14. Here
we see the differences between total deviation values
of both systems at individual locations with respect
to gradient measure, l, computed as described in the
literature.42,43 A high l means the location l is within
a nonhomogeneous region and potentially a deep local-
ized defect, which is important but more difficult to
exactly capture in a visual field testing. The median
error on relatively low l values, l < 15 dB, is less
than 5 dB for each group of subjects. As expected,
there are few occurrences of isolated nonhomogeneous
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Figure 7. Estimation bias on total deviation with respect to the eccentricity of the patient for healthy (left) and glaucoma (right) subjects.
P values are provided on each plot (Kruskal-Wallis test).
Figure 8. Mean (top row) and standard deviation (bottom row) of
TD differences with respect to the spatial location for healthy (left)
and glaucoma (right) subjects.
regions in healthy VFs. For relatively high l values
(i.e., l ≈ 20) dB, the median error is less than 3 dB
with higher standard deviation. As for glaucomatous
VFs, the median error is less than 8 dB for l ∈ [17−27
dB] and is within [10−15 dB] for larger l.
Regarding reliability comparison, we provide the
distributions of false positive (FPR) and false negative
response rates (FNR) for each device including all
(114) patients (without excluding patients based on
high FPR/FNR). The comparison given in Figure 15
and Table 2 show the distributions and the statistics
for healthy and glaucoma subjects separately to assess
if there is bias with respect to the patient’s VF state.
FPR of the proposed VR system is very similar to that
of Octopus 900 for both healthy and glaucoma groups,
even slightly lower in the VR (statistically significant
for the healthy group, Mann-WhitneyU test, P < 0.05;
statistically not significant for the glaucoma group,P>
0.1). FNR, however, tends to be slightly higher in the
VR system than in the Octopus 900 for both groups
(statistically significant for both healthy and glaucoma
groups, Mann-Whitney U test, P < 0.05).
Discussion
Mean defect comparison of the Octopus 900 and
the VR perimetry system using Spearman’s ranked
correlation showed good agreement between both
devicemeasurements with ρ being larger than 0.7 for all
and glaucomatous subjects. The lower ρ value obtained
for the healthy subjects can be explained by the low
variance of the corresponding data values (within the
range of –2.5 dB ≤ MD ≤ 2.5 dB), which reduces the
correlation coefficient (Constraining data to a small
range is known to reduce the correlation coefficient,
although the correlation on the whole range is high).
Therefore, the correlation plots including all patients
or glaucoma patients provide more meaningful infor-
mation with regards to the correlation between the two
measurements and demonstrated that the VRMDs are
well correlated with Octopus 900 MDs.
The estimation bias forMDmeasurements provided
in Figure 5 suggests almost no bias for healthy subjects
and a slight underestimation for glaucoma patients.
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Figure 9. Bland-Altman agreement graphs between Octopus 900 and VR device MD measurements. The black dotted line corresponds to
the mean difference and red dotted lines correspond to 95% limits of agreements (mean ± 1.96).
Figure 10. Distributions of examination duration for VR perimetry and Octopus 900 presented for all (left), healthy (middle), and glaucoma
patients (right). For each subplot, P values are provided (Kruskal-Wallis test).
Figure 11. Distributions of number of presented stimuli for VR perimetry and Octopus 900 for all (left), healthy (middle), and glaucoma
patients (right). For each subplot, P values are provided (Kruskal-Wallis test).
However, considering all patients, the bias is negligi-
ble with a mean difference of less than 1 dB. Inter-
estingly, the standard deviations of estimation differ-
ences are almost the same for normal and glaucoma
subjects. There was no dependence on particular age
groups in glaucoma patients (Kruskal-Wallis test, P
> 0.1) whereas, in healthy patients, we observed that
there is slight overestimation of MDs for age group
below 60 and underestimation for the group above 60
(Fig. 6). This can be partially explained by the fact that
with the increasing age subjects have relatively reduced
sensitivities, which our proposed system may not well
acquire due to its luminance limits. The overestimation
of MDby theVR system for relatively younger subjects
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Figure 12. Two healthy VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). The black
circle corresponds to the blind spot. Blue colors reflect higher devia-
tions, that is, deeper defects.
Figure 13. Two glaucomatous VF examples. Each row compares
acquisitions by VR perimetry (left) and by Octopus 900 (right). The
black circle corresponds to the blind spot. Blue colors reflect higher
deviations, that is, deeper defects.
should, however, be further investigated and verified
with more significant amount of data.
We also investigated the dependency of perfor-
mance with respect to eccentricity and spatial location
as given in Figure 7 and Figure 8. Accordingly, no
significant bias was observed with respect to the eccen-
tricity as shown in Figure 7 (Kruskal-Wallis test, P
> 0.1). As for the distribution of the TD differences
across the VF, we did not observe a clear trend of
dependency in either group; yet higher bias in the
peripheral region can be observed, especially in the
glaucoma group (Fig. 8). Interestingly, for healthy
subjects, there is only one location in the superior
hemisphere where VR remarkably underestimated with
high variance. Early visual field loss is known to start
developing from the peripheral region and mostly in
the superior hemifield,44,45 which can explain high
bias (i.e., underestimation by VR) and variance on
those regions due to both high response variabil-
ity and limited luminance of the proposed system.
Especially, the variance distribution appears to follow
the expansion of glaucomatous loss that affects has a
lesser effect on the inferior temporal region44,45 where
the variance of TD difference was also observed to
be low.
Alternatively, the Bland-Altman plots in Figure 9
illustrate the MD differences and stratify the MD
differences into the mean MD measurements. The
limits of agreements obtained for each group are found
to be comparable and even better than those reported
in similar comparative studies in the literature.23,46 This
indicates that the differences between MD measure-
ments are within acceptable error range.
While the examination duration was found to be
longer (≈ 1.3 minutes longer) for healthy patients
(Kruskal-Wallis test,P< 0.0001) and slightly longer for
glaucoma patients (no statistical significance, Kruskal-
Wallis test, P > 0.1), we mainly attribute this differ-
ence to the blind spot catch trials implemented in the
VR system, as well as to some implementation differ-
ences of perimetry strategies between the two devices.
When excluding the number of catch trials (see Fig. 11),
we observed that healthy patients requiredmore stimuli
while glaucoma patients required slightly less than
Octopus 900. The relatively higher number of stimuli
required by healthy patients is potentially due to the
smaller step sizes of our DS implementation in the VR
device within the dimmer intensity range. Conversely,
the smaller number of stimuli required by glaucoma
patients is due to the limited intensity range: since the
VR cannot present stimuli beyond the maximum inten-
sity of the VR headset, which is less than Octopus
900, this naturally decreases the number of stimuli
presented to glaucoma patients, especially at locations
with deeper defects.
Qualitative examples for healthy VFs acquired by
VR perimetry reflect overall coherence with those
acquired by Octopus 900 while some localized deep
defects in the VF by Octopus 900 may not be observed
in VRperimetry acquired VFs (see the bottom example
in Fig. 12). In some healthy cases, we observe local-
ized defects in the VR-acquired VFs as well, which
did not appear in their Octopus 900-acquired recip-
rocals (see Appendix). This may be due to implemen-
tation differences in DS, as well as to the occasional
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Figure 14. The differences between individual total deviation values with respect to the gradient measure l given for healthy and
glaucoma subjects separately. A highl value indicates that the corresponding locations are inside a heterogeneous region, which is more
difficult to accurately measure.
subject-specific reasons (e.g., novel experience with the
VR system). The existence of isolated defects in the
VR-acquired healthy VFs should be further investi-
gated with a test-retest study to better conclude on the
proposed system’s behavior. As for glaucoma examples,
we observed that VR perimetry could detect the spread
of defect regions correctly, but the defect magni-
tudes are slightly lower than those given by Octopus
900 (see Fig. 13 and Appendix). This bias is coher-
ent with Figure 5, where MDs were estimated lower
by VR than by Octopus 900 for glaucoma patients.
To better interpret the qualitative results, Figure 14
presents the individual errors (i.e., differences between
both systems) with respect to the gradient measure.
Here, the VR system had larger errors measuring
the defects at locations with high gradient measure
(i.e., less homogeneous region as also seen in the quali-
tative results). Yet, the error remains less than 8 dB
for the gradient measures smaller than 25 dB and only
gets very high for extremely deep and isolated defects
(i.e.,l > 27 dB). These high errors can be attributed to
the technical limits of the VR headset having a limited
range of luminance which restricts the measurement
of deep defects. Nonetheless, VR perimetry succeeds in
capturing defect patterns, although occasionally fails to
identify isolated defects.
In terms of reliability indices, Figure 15 shows
that the proposed VR system has similar reliability
behavior to the Octopus 900. We note that the FNR
tends to be slightly higher in healthy and glaucoma
groups when using our system. Such high FNRs may
be due to the limited luminance in our system which
cannot produce sufficiently higher intensity stimuli that
glaucoma patients with relatively higher visual field
defects need. However, FNRs generally remain under
a reasonable value (FNR ≤ 0.2) for each method
and for each group. Moreover, FNR as an indica-
tor of patience performance has been criticized and
has been shown to correlate with patient’s visual field
loss more than the patient’s reliability.47–49 This is also
seen in Figure 15: FPR distributions of each device
minimally change with respect to the patient group,
whereas the distributions of FNR change strongly
based on the patient group.Moreover, FNRs are higher
for glaucoma groups supporting the claim that FNR
may indicate more the VF state of the patient rather
than their performance.
There are several drawbacks of the presented work.
First, the proposed VR system has a limited luminance
range that does not allow advanced losses to be
measured as accurately as in conventional perimeters.
Another shortfall is the need for the calibration of the
VR screen luminosity, whichmay be affected by various
internal and external factors (i.e., device temperature,
battery level, etc.). This may induce additional noise
into the measurements. Moreover, the current clini-
cal study did not investigate the test-retest variabil-
ity as well as the diagnostic utility of the proposed
system, which are important metrics in assessing the
performance of a perimeter. Given these limitations,
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Figure 15. Distributions of the reliability indices, namely false positive (left)/negative (right) response rates of eachdevice. For each subplot,
P values are provided (Mann-Whitney U test).
our future work will focus on overcoming the VR
perimetry technical limits to standardize the measure-
ments, generating a normative database based on a
larger normal healthy population to assess its diagnos-
tic performance and designing a test-retest clinical
study to show the test repeatability performance.
Table 2. Summary of Catch Trial False Positive Rates (FPR) and False Negative Rates (FNR) for Healthy and Glauco-




Healthy Octopus 900 0.00/0.08/0.12 0.00/0.03/0.11
VR 0.00/0.04/0.07 0.00/0.05/0.09
Glaucoma Octopus 900 0.00/0.07/0.12 0.00/0.07/0.11
VR 0.00/0.08/0.15 0.10/0.16/0.21
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Conclusions
This study presents clinical results comparing the
performances of a novel virtual reality–based perime-
try system with a conventional stationary perimeter,
Octopus 900. The proposed VR perimetry system
simulates a standard visual field testing by presenting
a sequential light stimulus to the patient who gives
feedback with an associated clicker. In this study, we
evaluated the proposed system on 70 subjects, includ-
ing normal healthy subjects and glaucomapatients. The
VFs acquired by the VR perimetry showed high corre-
lation (ρ > 0.7) with those given by the Octopus 900.
Qualitatively, VR perimetry could correctly identify the
impaired areas in a VF while deep isolated defects were
occasionally underestimated. With its portability and
comfort, VR perimetry has great potential to become
an alternative to conventional perimeters in the future.
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Appendix: Qualitative Examples
In this appendix, we present qualitative compar-
isons of two acquired VFs for each subject included
into the study.
Figure 16. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is, deeper defects.
Figure 17. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is, deeper defects.
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Figure 18. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is, deeper defects.
Figure 19. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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Figure 20. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
Figure 21. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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Figure 22. Five healthy VF examples. Each row compares acquisi-
tions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
Figure 23. One healthy VF example. It compares acquisitions by
VR perimetry (left) and by Octopus 900 (right). Black circle corre-
sponds to the blind spot. Bluish colors reflect higher deviations, that
is , deeper defects.
Figure 24. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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Figure 25. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
Figure 26. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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Figure 27. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
Figure 28. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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Figure 29. Five glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
Figure 30. Four glaucoma VF examples. Each row compares acqui-
sitions by VR perimetry (left) and by Octopus 900 (right). Black circle
corresponds to the blind spot. Bluish colors reflect higher deviations,
that is , deeper defects.
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